AlphaYouAKTS: Czibere Akos discloses securities transactions
By AlphaYouPublished Form 4
Czibere Akos
Reporting filer
Czibere Akos reported Exercise or conversion in Aktis Oncology, Inc.: 12500 units of Common Stock, dated 2026-09-23. The full Form 4 contains 4 transaction entries.
- Disclosed
- Sep 24, 2026
Reported details
4 entries| Security | Owner | Date | Code | Action | Quantity | Price | Following holdings | Reporting delay | Filed terms and references |
|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Czibere Akos | 2026-09-23 | M | Exercise or conversion | 12500 | 4.95 | 12,500 | 1 day | Filed terms
|
| Common Stock | Czibere Akos | 2026-09-23 | S | Sale | 5099 | 20.1947 | 7,401 | 1 day | Filed terms
|
| Common Stock | Czibere Akos | 2026-09-23 | S | Sale | 7401 | 21.0307 | 0 | 1 day | Filed terms
|
| Stock Option (Right to Buy) (derivative) | Czibere Akos | 2026-09-23 | M | Exercise or conversion | 12500 | 0 | 208,718 | 1 day | Filed terms
|
Common Stock
- Owner
- Czibere Akos
- Date
- 2026-09-23
- Code
- M
- Action
- Exercise or conversion
- Quantity
- 12500
- Price
- 4.95
- Following holdings
- 12,500
- Reporting delay
- 1 day
- Filed terms and references
Filed terms
- security Title: Common Stock
- transaction Date: 2026-09-23
- transaction Form Type: 4
- transaction Code: M
- equity Swap Involved: false
- id: F1
- transaction Shares: 12500
- transaction Price Per Share: 4.95
- transaction Acquired Disposed Code: A
- shares Owned Following Transaction: 12500
- direct Or Indirect Ownership: D
Common Stock
- Owner
- Czibere Akos
- Date
- 2026-09-23
- Code
- S
- Action
- Sale
- Quantity
- 5099
- Price
- 20.1947
- Following holdings
- 7,401
- Reporting delay
- 1 day
- Filed terms and references
Filed terms
- security Title: Common Stock
- transaction Date: 2026-09-23
- transaction Form Type: 4
- transaction Code: S
- equity Swap Involved: false
- id: F1
- transaction Shares: 5099
- transaction Price Per Share: 20.1947
- id: F2
- transaction Acquired Disposed Code: D
- shares Owned Following Transaction: 7401
- direct Or Indirect Ownership: D
Common Stock
- Owner
- Czibere Akos
- Date
- 2026-09-23
- Code
- S
- Action
- Sale
- Quantity
- 7401
- Price
- 21.0307
- Following holdings
- 0
- Reporting delay
- 1 day
- Filed terms and references
Filed terms
- security Title: Common Stock
- transaction Date: 2026-09-23
- transaction Form Type: 4
- transaction Code: S
- equity Swap Involved: false
- id: F1
- transaction Shares: 7401
- transaction Price Per Share: 21.0307
- id: F3
- transaction Acquired Disposed Code: D
- shares Owned Following Transaction: 0
- direct Or Indirect Ownership: D
Stock Option (Right to Buy) (derivative)
- Owner
- Czibere Akos
- Date
- 2026-09-23
- Code
- M
- Action
- Exercise or conversion
- Quantity
- 12500
- Price
- 0
- Following holdings
- 208,718
- Reporting delay
- 1 day
- Filed terms and references
Filed terms
- security Title: Stock Option (Right to Buy)
- conversion Or Exercise Price: 4.95
- transaction Date: 2026-09-23
- transaction Form Type: 4
- transaction Code: M
- equity Swap Involved: false
- id: F1
- transaction Shares: 12500
- transaction Price Per Share: 0
- transaction Acquired Disposed Code: D
- id: F4
- expiration Date: 2034-06-30
- underlying Security Title: Common Stock
- underlying Security Shares: 12500
- shares Owned Following Transaction: 208718
- direct Or Indirect Ownership: D
Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.
Filing context
- Quantities and prices are shown in the units filed. No trade value is inferred from their product.
- Czibere Akos: Chief Medical Officer.
- The filing reports a Rule 10b5-1 trading plan.
- F1: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2026.
- F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.6700 to $20.6500, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.6700 to $21.5000, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4: 25% of the original number of shares subject to the option vested on July 1, 2025, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.
Original sources
Prepared automatically from public filing data. Report a correction.